<DOC>
	<DOCNO>NCT01165944</DOCNO>
	<brief_summary>Post-transplant diabetes mellitus ( PTDM ) develop 30 % patient undergoing solid organ transplantation . This disease difficult treat level glycemia fluctuate response variation dose steroid immunosuppressive agent . At time , poorly control hyperglycemia affect negatively graft function survival well ability immunocompromised host fight infection . The investigator hypothesize addition Pramlintide ( Symlin ) management patient PTDM would help patient post-transplant diabetes attain good control critical time titration immunosuppressive regimen . The primary objective proposal improve glycemic control diabetes Pramlintide patient post-transplant diabetes 3 6 month therapy .</brief_summary>
	<brief_title>Effectiveness Study Pramlintide Treat Post-Transplant Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Pramlintide</mesh_term>
	<mesh_term>Islet Amyloid Polypeptide</mesh_term>
	<criteria>Posttransplant diabetes ( PTMD ) Aged 2070 Diagnosis diabetes within last 618 month Stable medication Stable weight 3 month Serum creatinine &lt; 1.5 mg/dL Pretransplant diabetes Major postoperative complication follow transplant Pregnancy Significant GI discomfort nausea vomit Inability learn continuous glucose monitoring Development diabetes 4 year transplant omen childbearing potential use birth control pills fast triglyceride &gt; 400 mg/dL</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Post transplant diabetes mellitus</keyword>
</DOC>